3SBIO (01530.HK), a leading Chinese biopharmaceutical company, saw its stock price surge 5.19% in pre-market trading on Wednesday following the release of impressive full-year financial results and the announcement of a final dividend.
The company reported robust financial performance for the fiscal year, with revenue reaching RMB 9,108 million. 3SBIO demonstrated strong profitability, posting a basic earnings per share (EPS) of RMB 0.86 and maintaining an exceptionally high gross margin of 86%. The gross profit stood at RMB 7,828.4 million, while EBITDA and adjusted EBITDA came in at RMB 3,173.8 million and RMB 3,402.3 million, respectively.
Adding to investor enthusiasm, 3SBIO declared a final dividend of HKD25 cents per share, signaling confidence in the company's financial health and commitment to shareholder returns. This combination of strong financial results and a generous dividend payout appears to have fueled the significant pre-market rally, as investors respond positively to the company's performance and shareholder-friendly policies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.